Side-by-side · Research reference
KPVvsMT-1
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongAUTO-DRAFTED13/39 cited
BFDA-ApprovedHUMAN-REVIEWED9/51 cited
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
MT-1
α-MSH Analogue · FDA-Approved
SQ Implant · 60-Day Release
01Mechanism of Action
Parameter
KPV
MT-1
Primary target
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010
Pathway
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis
Downstream effect
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010
Feedback intact?
No melanocortin receptor binding
Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production
Origin
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026
Antibody development
—
—
02Dosage Protocols
Parameter
KPV
MT-1
Standard dose
200–500 mcg / day SQ or oralDalle-Pang 2024
16 mg subcutaneous implant
FDA-approved formulation (Scenesse).
Frequency
Daily or 2–3× per week
Every 60 days
Sustained release implant — no daily administration required.
Lower / starter dose
100 mcg / day
—
Evidence basis
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Phase 3 RCT / FDA-approved orphan drug
Duration
4–8 weeks per cycle
Seasonal use (spring–autumn typical)
Aligned with peak UV exposure months.
Reconstitution
Bacteriostatic water (SQ form)
—
Timing
No specific time; often taken with / before meals (oral)
—
Half-life
Hours (estimated; rapid tissue uptake)
—
Indication
—
Erythropoietic protoporphyria (EPP)
Narrow FDA approval — not licensed for cosmetic tanning.
Route
—
Subcutaneous implant — upper arm or abdomen
Stability
—
Norleucine/D-Phe substitutions enhance peptidase resistance
Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).
04Side Effects & Safety
Parameter
KPV
MT-1
Injection site reaction
Mild irritation
—
GI symptoms
Rare nausea (oral form)
—
Long-term safety
Limited human data
—
Pregnancy / OB
Avoid — insufficient data
—
Nausea
—
Common (>10%) — mild, transient
Implant site reaction
—
Erythema, bruising, tenderness at insertion site
Hyperpigmentation
—
Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010Habbema 2017
Expected melanogenic response — complicates pigmented lesion surveillance.
Melanocytic changes
—
Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017
Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.
Headache
—
Occasional (MC1R-independent melanocortin effects)
Photosensitivity (paradoxical)
—
Rare phototoxic reactions despite melanin increase
Contamination risk (unregulated)
—
Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010Habbema 2017
Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.
Absolute Contraindications
KPV
- ·Pregnancy / breastfeeding
MT-1
- ·Hypersensitivity to afamelanotide or excipients
- ·Hepatic impairment (no safety data)
- ·Renal impairment (no safety data)
Relative Contraindications
KPV
- ·Active autoimmune disease (theoretical)
MT-1
- ·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
- ·Pregnancy/lactation (insufficient data)
- ·Photosensitive dermatoses (other than EPP)
05Administration Protocol
Parameter
KPV
MT-1
1. Reconstitution
Add 1 mL bacteriostatic water to vial per labelling.
Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.
2. Form
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.
3. Timing
Morning preferred; oral form taken with / before meals.
Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.
5. Needle
29–31G insulin syringe (SQ form).
Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.
06Stack Synergy
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions
MT-1
— no documented stacks